Bioxcel therapeutics announces u.s. department of defense grant to university of north carolina to fund study of bxcl501 (sublingual dexmedetomidine) for treating acute stress disorder

Phase 2a efficacy and safety trial enrollment initiation expected in h1 2025 ~ 40 million americans go to emergency department annually after a traumatic experience 1 second externally funded stress-related trial for bxcl501 new haven, conn., oct. 15, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced a collaboration with the university of north carolina at chapel hill (unc) on a grant awarded by the u.s. department of defense (dod) to evaluate the efficacy and safety of bxcl501 as a potential treatment for acute stress disorder (asd).
BTAI Ratings Summary
BTAI Quant Ranking